$OPCH
Option Care Health, Inc. Stock $opch

$opch Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000101473915000009 Filed on May 08, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q1
Revenue	$246.9M	$244.4M	$239.3M
YoY Change	-0.09%	2.11%	32.12%
Cost Of Revenue	$182.1M	$179.4M	$174.2M
YoY Change	0.17%	2.99%	39.19%
Gross Profit	$64.82M	$64.96M	$62.14M
YoY Change	4.13%	4.53%	10.99%
Gross Profit Margin	26.25%	26.58%	25.97%
Selling, General & Admin	$27.00M	$20.00M	$65.80M
YoY Change	-54.85%	-69.6%	31.34%
% of Gross Profit	41.66%	30.79%	105.89%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.130M	$5.794M	$3.836M
YoY Change	4.35%	51.04%	58.64%
% of Gross Profit	6.37%	8.92%	6.17%
Operating Expenses	$76.50M	$67.50M	$65.30M
YoY Change	34.92%	3.37%	25.1%
Operating Profit	-$254.0M	-$6.203M	-$11.27M
YoY Change	3860.78%	-44.94%	415.13%
Interest Expense	-$9.100M	-$9.200M	$10.50M
YoY Change	-199.62%	-187.63%	62.07%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$264.8M	-$15.37M	-$23.61M
YoY Change	1437.79%	-34.9%	176.48%
Income Tax	-$19.92M	$1.928M	$3.491M
% Of Pretax Income
Net Earnings	-$244.8M	-$19.67M	-$25.31M
YoY Change	1135.28%	-22.28%	211.44%
Net Earnings / Revenue	-99.15%	-8.05%	-10.58%
Basic Earnings Per Share			-$0.37
Diluted Earnings Per Share	-$14.23M	-$1.145M	-$1.480M
COMMON SHARES
Basic Shares Outstanding	68.65M shares	68.64M shares	68.17M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.200M	$23.20M	$9.300M
YoY Change	-20.0%	149.46%
Cash & Equivalents	$1.173M	$23.25M	$9.253M
Short-Term Investments
Other Short-Term Assets	$10.40M	$10.60M	$12.30M
YoY Change	-15.45%	-13.82%	35.16%
Inventory	$42.36M	$41.88M	$34.75M
Prepaid Expenses
Receivables	$131.5M	$136.7M	$195.1M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$185.4M	$212.4M	$251.3M
YoY Change	-22.36%	-15.51%	32.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.91M	$35.93M	$39.95M
YoY Change	-12.43%	-10.06%	43.89%
Goodwill	$335.3M	$573.3M	$571.8M
YoY Change	-41.47%	0.26%	38.05%
Intangibles			$15.12M
YoY Change			-21.91%
Long-Term Investments
YoY Change
Other Assets	$1.192M	$1.247M	$3.576M
YoY Change	-9.56%	-65.13%	158.19%
Total Long-Term Assets	$391.7M	$633.1M	$648.7M
YoY Change	-39.27%	-2.41%	36.38%
TOTAL ASSETS
Total Short-Term Assets	$185.4M	$212.4M	$251.3M
Total Long-Term Assets	$391.7M	$633.1M	$648.7M
Total Assets	$577.1M	$845.4M	$900.1M
YoY Change	-34.7%	-6.07%	35.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$77.09M	$91.11M	$68.29M
YoY Change	10.52%	33.42%	112.68%
Accrued Expenses	$47.60M	$43.70M	$45.00M
YoY Change	4.16%	-2.89%	-8.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$300.0K	$400.0K
YoY Change	-50.0%	-25.0%	-98.57%
Total Short-Term Liabilities	$134.0M	$145.2M	$127.6M
YoY Change	6.72%	13.79%	-4.2%
LONG-TERM LIABILITIES
Long-Term Debt	$418.6M	$418.5M	$418.2M
YoY Change	0.07%	0.07%	85.54%
Other Long-Term Liabilities	$6.891M	$2.656M	$8.940M
YoY Change	-19.68%	-70.29%	-0.35%
Total Long-Term Liabilities	$6.891M	$2.656M	$8.940M
YoY Change	-19.68%	-70.29%	-0.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$134.0M	$145.2M	$127.6M
Total Long-Term Liabilities	$6.891M	$2.656M	$8.940M
Total Liabilities	$562.5M	$587.2M	$567.4M
YoY Change	-1.12%	3.49%	50.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$566.7M	-$321.9M	-$180.1M
YoY Change	183.53%	78.77%	93.16%
Common Stock	$534.1M	$536.8M	$523.0M
YoY Change	1.7%	2.64%	33.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$10.72M	$10.72M	$10.31M
YoY Change	3.92%	3.92%	0.0%
Treasury Stock Shares	2.645M shares	2.645M shares	2.583M shares
Shareholders Equity	-$43.29M	$204.2M	$332.7M
YoY Change
Total Liabilities & Shareholders Equity	$577.1M	$845.4M	$900.1M
YoY Change	-34.7%	-6.07%	35.2%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$244.8M	-$19.67M	-$25.31M
YoY Change	1135.28%	-22.28%	211.44%
Depreciation, Depletion And Amortization	$4.130M	$5.794M	$3.836M
YoY Change	4.35%	51.04%	58.64%
Cash From Operating Activities	-$18.20M	-$28.05M	-$25.99M
YoY Change	264.0%	7.93%	102.26%
INVESTING ACTIVITIES
Capital Expenditures	-$3.700M	-$2.100M	-$3.100M
YoY Change	-2.63%	-32.26%	-13.89%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	$0.00	$0.00	$56.60M
YoY Change	-100.0%	-100.0%	-177.22%
Cash From Investing Activities	-$3.700M	-$2.066M	$53.56M
YoY Change	12.12%	-103.86%	-169.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-200.0K	$52.62M	-$19.32M
YoY Change	-140.0%	-372.38%	-169.92%
NET CHANGE
Cash From Operating Activities	-18.20M	-$28.05M	-$25.99M
Cash From Investing Activities	-3.700M	-$2.066M	$53.56M
Cash From Financing Activities	-200.0K	$52.62M	-$19.32M
Net Change In Cash	-22.10M	$22.51M	$8.252M
YoY Change	183.33%	172.73%	-113.29%
FREE CASH FLOW
Cash From Operating Activities	-$18.20M	-$28.05M	-$25.99M
Capital Expenditures	-$3.700M	-$2.100M	-$3.100M
Free Cash Flow	-$14.50M	-$25.95M	-$22.89M
YoY Change	1108.33%	13.37%	147.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	bios	Increase Decreasein Amounts Due To Plan Sponsor IncreaseDecreaseinAmountsDueToPlanSponsor	-1575000	USD
CY2014Q4	bios	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	46092000	USD
CY2015Q1	bios	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	41478000	USD
CY2014Q1	bios	Acquisition And Integration Expenses AcquisitionAndIntegrationExpenses	6499000	USD
CY2015Q1	bios	Acquisition And Integration Expenses AcquisitionAndIntegrationExpenses	220000	USD
CY2014Q1	bios	Adjusted Ebitda AdjustedEbitda	16636000	USD
CY2015Q1	bios	Adjusted Ebitda AdjustedEbitda	14088000	USD
CY2015Q1	bios	Adjustmentsto Additional Paidin Capital Accretionof Discounton Temporary Equity AdjustmentstoAdditionalPaidinCapitalAccretionofDiscountonTemporaryEquity	1164000	USD
CY2015Q1	bios	Adjustmentsto Additional Paidin Capital Increasein Liquidation Preferenceon Temporary Equity AdjustmentstoAdditionalPaidinCapitalIncreaseinLiquidationPreferenceonTemporaryEquity	453000	USD
CY2015Q1	bios	Adjustmentsto Additional Paidin Capital Private Investmentin Public Equity Transaction AdjustmentstoAdditionalPaidinCapitalPrivateInvestmentinPublicEquityTransaction	6570000	USD
CY2014Q4	bios	Allowancefor Doubtful Accounts Percentageof Accounts Receivable AllowanceforDoubtfulAccountsPercentageofAccountsReceivable	0.321
CY2015Q1	bios	Allowancefor Doubtful Accounts Percentageof Accounts Receivable AllowanceforDoubtfulAccountsPercentageofAccountsReceivable	0.328
CY2014Q4	bios	Amounts Due To Plan Sponsors AmountsDueToPlanSponsors	5779000	USD
CY2015Q1	bios	Amounts Due To Plan Sponsors AmountsDueToPlanSponsors	4203000	USD
CY2015Q1	bios	Classof Warrantor Right Exercise Priceof Warrantsor Rights Percentageof Market Price ClassofWarrantorRightExercisePriceofWarrantsorRightsPercentageofMarketPrice	0.85
CY2015Q1	bios	Finite Lived Intangible Assets Amortization Expense Year Fiveand Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandThereafter	0	USD
CY2014Q1	bios	Gain Losson Changein Fair Valueof Contingent Consideration GainLossonChangeinFairValueofContingentConsideration	2209000	USD
CY2015Q1	bios	Gain Losson Changein Fair Valueof Contingent Consideration GainLossonChangeinFairValueofContingentConsideration	-21000	USD
CY2014Q1	bios	Increase Decreasein Amounts Due To Plan Sponsor IncreaseDecreaseinAmountsDueToPlanSponsor	1138000	USD
CY2014Q1	bios	Increase Decreasein Fair Valueof Contingent Consideration IncreaseDecreaseinFairValueofContingentConsideration	2209000	USD
CY2015Q1	bios	Increase Decreasein Fair Valueof Contingent Consideration IncreaseDecreaseinFairValueofContingentConsideration	-21000	USD
CY2015Q1	bios	Increasein Accounts Receivable Outstandingover One Hundred Eight Days IncreaseinAccountsReceivableOutstandingoverOneHundredEightDays	3300000	USD
CY2014Q4	bios	Long Term Debt And Capital Lease Obligations Total LongTermDebtAndCapitalLeaseObligationsTotal	423803000	USD
CY2015Q1	bios	Long Term Debt And Capital Lease Obligations Total LongTermDebtAndCapitalLeaseObligationsTotal	418828000	USD
CY2014	bios	Number Of Large Markets NumberOfLargeMarkets	7	Market
CY2014	bios	Number Of Legacy Billing Systems NumberOfLegacyBillingSystems	5	System
CY2015Q1	bios	Number Of Types Of Accounts Receivable NumberOfTypesOfAccountsReceivable	3	accounts_receivable
CY2014Q1	bios	Other Interest Income Expense Net OtherInterestIncomeExpenseNet	85000	USD
CY2015Q1	bios	Other Interest Income Expense Net OtherInterestIncomeExpenseNet	175000	USD
CY2014Q1	bios	Proceedsfrom Issuanceof Convertible Preferred Stockand Warrants ProceedsfromIssuanceofConvertiblePreferredStockandWarrants	0	USD
CY2015Q1	bios	Proceedsfrom Issuanceof Convertible Preferred Stockand Warrants ProceedsfromIssuanceofConvertiblePreferredStockandWarrants	58951000	USD
CY2015Q1	bios	Proceedsfrom Issuanceof Equityand Temporary Equity ProceedsfromIssuanceofEquityandTemporaryEquity	62500000	USD
CY2015Q1	bios	Proceedsfrom Issuanceof Temporary Equity ProceedsfromIssuanceofTemporaryEquity	59355000	USD
CY2015Q1	bios	Registration Rights Agreement Periodof Timebefore Rights Become Effective RegistrationRightsAgreementPeriodofTimebeforeRightsBecomeEffective	P1Y
CY2015Q1	bios	Repayments Of Debt Including Accrued Interest RepaymentsOfDebtIncludingAccruedInterest	45300000	USD
CY2014Q1	bios	Restructuring Charges Other Expensesand Investments RestructuringChargesOtherExpensesandInvestments	5502000	USD
CY2015Q1	bios	Restructuring Charges Other Expensesand Investments RestructuringChargesOtherExpensesandInvestments	3463000	USD
CY2015Q1	bios	Stock Purchase Agreement Covenant Terms Minimum Percentageof Proceedstobe Usedon Repaymentof Debt StockPurchaseAgreementCovenantTermsMinimumPercentageofProceedstobeUsedonRepaymentofDebt	0.75
CY2014Q1	bios	Transitional Expenses TransitionalExpenses	700000	USD
CY2015Q1	bios	Transitional Expenses TransitionalExpenses	2400000	USD
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001014739
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68650271	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	BioScrip, Inc.
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	90032000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	91110000	USD
CY2014Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	207310000	USD
CY2015Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	203497000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	140810000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	136661000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	50643000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54322000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	529682000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	536814000	USD
CY2015Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	36000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2959000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2179000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	66500000	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	66836000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	66500000	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	66836000	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	300000	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	66000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	140000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1877000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	641000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1943000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	780000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1703000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1490000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	60000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	116000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	282000	USD
CY2014Q1	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	500000	USD
CY2015Q1	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	600000	USD
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3800000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5800000	shares
CY2014Q4	us-gaap	Assets Assets	824713000	USD
CY2015Q1	us-gaap	Assets Assets	845423000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	188215000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	212353000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	469000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	11000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1001000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9253000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	740000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23246000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8252000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22506000	USD
CY2014Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	56616000	USD
CY2015Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2014Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1671000	USD
CY2015Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3768000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71274064	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71295564	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68636965	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68650271	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2015Q1	us-gaap	Contractual Obligation ContractualObligation	31015000	USD
CY2015Q1	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	2357000	USD
CY2015Q1	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	2731000	USD
CY2015Q1	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	4546000	USD
CY2015Q1	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	7766000	USD
CY2015Q1	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	6643000	USD
CY2015Q1	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	6972000	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	174193000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	195208000	USD
CY2014Q1	us-gaap	Cost Of Services CostOfServices	22453000	USD
CY2015Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7476000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7768000	USD
CY2014Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	783000	USD
CY2015Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	573323000	USD
CY2015Q1	us-gaap	Goodwill Goodwill	573323000	USD
CY2014Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	783000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	67000	USD
CY2015Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2014Q1	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2396000	USD
CY2015Q1	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1628000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	13463000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1983000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3078000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	33350000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	33350000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10269000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8780000	USD
CY2015Q1	us-gaap	Cost Of Services CostOfServices	21261000	USD
CY2014Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	13788000	USD
CY2014Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2708000	USD
CY2015Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1927000	USD
CY2014Q1	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	312000	USD
CY2015Q1	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	299000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	19058000	USD
CY2015Q1	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	20879000	USD
CY2014Q1	us-gaap	Depreciation Depreciation	3836000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	4304000	USD
CY2014Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0
CY2015Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.05
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23081000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24570000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3652000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	65100000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	66473000	USD
CY2014Q1	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	151740000	USD
CY2015Q1	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	173947000	USD
CY2014Q1	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	215903000	USD
CY2015Q1	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	239047000	USD
CY2014Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	23390000	USD
CY2015Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	22634000	USD
CY2014Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	239293000	USD
CY2014Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-58000	USD
CY2015Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-3768000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1475000	USD
CY2015Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	261681000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-25256000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15905000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21765000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13977000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.37
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.26
CY2014Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
CY2015Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.05
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3491000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1928000	USD
CY2014Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10601000	USD
CY2015Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6781000	USD
CY2014Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7670000	USD
CY2015Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4892000	USD
CY2014Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	51000	USD
CY2015Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	39000	USD
CY2014Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	509000	USD
CY2015Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2014Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-314000	USD
CY2015Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	528000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	4644000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1077000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-2708000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1927000	USD
CY2014Q1	us-gaap	Increase Decrease In Future Policy Benefit Reserves IncreaseDecreaseInFuturePolicyBenefitReserves	5365000	USD
CY2015Q1	us-gaap	Increase Decrease In Future Policy Benefit Reserves IncreaseDecreaseInFuturePolicyBenefitReserves	-2386000	USD
CY2014Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	134000	USD
CY2015Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-4585000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	413000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4666000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	634000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-9729000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	838000	USD
CY2014Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	22903000	USD
CY2015Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4149000	USD
CY2014Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-10499000	USD
CY2015Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9163000	USD
CY2014Q1	us-gaap	Interest Paid Net InterestPaidNet	8476000	USD
CY2015Q1	us-gaap	Interest Paid Net InterestPaidNet	13748000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	6853000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	37215000	USD
CY2015Q1	us-gaap	Interest Payable Current InterestPayableCurrent	2268000	USD
CY2014Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1211000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	41881000	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2000000	USD
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1800000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	607908000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	587197000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	824713000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	845423000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	162313000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	145159000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	418408000	USD
CY2015Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	418503000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5395000	USD
CY2015Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	325000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-19318000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52619000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	53556000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2066000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3060000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2066000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25986000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28047000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-24315000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-24279000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-25314000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-19673000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25314000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21290000	USD
CY2014Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2014Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11266000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4814000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	30546000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2731000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4535000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6583000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7650000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2357000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	6690000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1272000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1247000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8129000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2656000	USD
CY2014Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	59180000	USD
CY2015Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	57773000	USD
CY2014Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	3060000	USD
CY2015Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	2066000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4175000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1218000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4000000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6601000	USD
CY2015Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8320000	USD
CY2015Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	35000000	USD
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	140810000	USD
CY2015Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	136661000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	98000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	114000	USD
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9450000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10565000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	193810000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3145000	USD
CY2014Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	64600000	USD
CY2015Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	74963000	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-172243000	USD
CY2015Q1	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	427000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	88814000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90254000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38171000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35932000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	104603000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	79963000	USD
CY2014Q1	us-gaap	Restructuring Charges RestructuringCharges	4592000	USD
CY2015Q1	us-gaap	Restructuring Charges RestructuringCharges	3463000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-302206000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321879000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2886000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1657000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	428000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	354583000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	332656000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	216805000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	204228000	USD
CY2014Q4	us-gaap	Supplementary Insurance Information Liability For Future Policy Benefits Losses Claims And Loss Expense Reserves SupplementaryInsuranceInformationLiabilityForFuturePolicyBenefitsLossesClaimsAndLossExpenseReserves	8162000	USD
CY2015Q1	us-gaap	Supplementary Insurance Information Liability For Future Policy Benefits Losses Claims And Loss Expense Reserves SupplementaryInsuranceInformationLiabilityForFuturePolicyBenefitsLossesClaimsAndLossExpenseReserves	5775000	USD
CY2014Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2015Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1164000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2015Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	53998000	USD
CY2014Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2015Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	453000	USD
CY2015Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	62952911	USD
CY2015Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2015Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	825000	shares
CY2015Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	625000	shares
CY2015Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	625000	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2637099	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	2645293	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	10679000	USD
CY2015Q1	us-gaap	Treasury Stock Value TreasuryStockValue	10715000	USD
CY2015Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2900000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68171000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68637000	shares
CY2015Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 31, 2014 the Company completed the sale of substantially all of its Home Health Services segment to LHC Group, Inc. (see Note 6 - Discontinued Operations). As a result of the sale of the Home Health Services segment, the Company operates in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> operating and reportable segments, “Infusion Services” and “PBM Services”. All prior period financial statements have been reclassified to include the Home Health Services segment as discontinued operations. In addition, other classification changes have been made which have no material effect on the Company’s previously reported consolidated financial position, results of operations or cash flows.</font></div></div>
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2014, the Company experienced deterioration in the aging of certain accounts receivable primarily due to delays and disruptions related to the integration of its acquisitions in 2013. The disruption to billing and collection processes was attributable in part to the following:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Re-licensure and new managed care credentialing was required in connection with the CarePoint Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare claims were not filed until retraining and review of eligibility was performed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merged facilities and work teams in </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> large markets and related employee turnover;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion to a single version of our dispensing and billing system while still managing accounts receivable run-off on </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> other legacy versions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash posting challenges that delayed secondary and patient billings and patient statement issuance.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company outsourced collections to third party agency partners and hired and trained billing and collection personnel to mitigate the effects of the disruption, however, the Company experienced more difficulty collecting the aged balances than it originally estimated. The Company provided incremental allowances in each quarter during 2014 to address the developing deterioration, and as such the Company materially changed its estimates based on actual collection experience during and after the acquisition disruption period. </font></div></div>

Files In Submission

Name	View Source	Status
0001014739-15-000009-index-headers.html	Edgar Link	pending
0001014739-15-000009-index.html	Edgar Link	pending
0001014739-15-000009.txt	Edgar Link	pending
0001014739-15-000009-xbrl.zip	Edgar Link	pending
bios-20150331.xml	Edgar Link	completed
bios-20150331.xsd	Edgar Link	pending
bios-20150331x10q.htm	Edgar Link	pending
bios-20150331_cal.xml	Edgar Link	unprocessable
bios-20150331_def.xml	Edgar Link	unprocessable
bios-20150331_lab.xml	Edgar Link	unprocessable
bios-20150331_pre.xml	Edgar Link	unprocessable
bios-ex106x2015033110xqsti.htm	Edgar Link	pending
bios-ex311x2015033110xq.htm	Edgar Link	pending
bios-ex312x2015033110xq.htm	Edgar Link	pending
bios-ex321x2015033110xq.htm	Edgar Link	pending
bios-ex322x2015033110xq.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
logowithregisteredtrademark.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stiverbrianamendmentt_image1.gif	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPCH
Option Care Health, Inc. Stock $opch

2015 Q2 Form 10-Q Financial Statement

#000101473915000009 Filed on May 08, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPCH Option Care Health, Inc. Stock $opch

2015 Q2 Form 10-Q Financial Statement

#000101473915000009 Filed on May 08, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPCH
Option Care Health, Inc. Stock $opch